Prognosis
Pfizer, Eli Lilly Breakthroughs Provide Hope for Ending Pandemic
- Euphoria somewhat offset by China trial halt in Brazil
- At least 13 places already have supply agreements with Pfizer
This article is for subscribers only.
Almost a year into the pandemic, a world facing the unrelenting spread of the coronavirus received a burst of good news, with a vaccine developed by Pfizer Inc. showing “extraordinary” results while an antibody therapy from Eli Lilly & Co. was granted emergency-use authorization in the U.S.
The double shot of progress was somewhat offset by news that the final-stage trial of a frontrunner Chinese vaccine candidate was halted in Brazil due to a serious adverse event, the first time that the Asian nation’s rapidly ascendant shots have met such a setback.